Michael D. West, Ph.D.
CHIEF EXECUTIVE OFFICER
Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular ageing. He has focused his academic and business career on the application of developmental biology to age-related degenerative disease. He was the founder and first CEO of Geron Corporation (Nasdaq: GERN), and from 1992 to 1998, he held various positions, including CEO, Director, and Vice President. From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX).
Our Team
Michael D. West, Ph.D.
CHIEF EXECUTIVE OFFICER
Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular ageing. He has focused his academic and business career on the application of developmental biology to age-related degenerative disease. He was the founder and first CEO of Geron Corporation (Nasdaq: GERN), and from 1992 to 1998, he held various positions, including CEO, Director, and Vice President. From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX).
Nafees Malik, M.D.
CHIEF OPERATING OFFICER
Nafees Malik, M.D., is Chief Operating Officer at AgeX Therapeutics. He is an M.D. with a Master’s degree from the University of Cambridge. His 15 year career has involved roles spanning clinical medicine, investment banking, biopharmaceutical companies, research and academic institutions, and strategy consulting. For many years now, he has focused on the strategic and commercial analysis of cell and gene therapies and regenerative medicines. He is also Head of Cell and Gene Therapy at Juvenescence.
Andrea E. Park, CPA (inactive)
CHIEF FINANCIAL OFFICER
Andrea E. Park, CPA (inactive) was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Prior to that, Ms. Park served as the company’s VP of Finance and Controller since October 2019. As CFO, Ms. Park is responsible for all of the company’s financial functions including accounting, internal and external audits, tax, and treasury. Ms. Park’s career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as VP of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from February 2005 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporate and AgeX. Earlier in her career she has worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.
Hal Sternberg, Ph.D.
VP, RESEARCH
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.
Judith Segall
DIRECTOR – ADMINISTRATION
CORPORATE SECRETARY
Judith Segall is our Director of Administration and Corporate Secretary. Prior to joining AgeX, Ms. Segall was the Vice President of Administration of BioTime, Inc. As one of BioTime’s co-founders in 1990, she served on the BioTime Board of Directors and as an executive for over 25 years. Ms. Segall received her B.S. in Nutrition and Clinical Dietetics from the University of California at Berkeley.
Nafees Malik, M.D.
CHIEF OPERATING OFFICER
Nafees Malik, M.D., is Chief Operating Officer at AgeX Therapeutics. He is an M.D. with a Master’s degree from the University of Cambridge. His 15 year career has involved roles spanning clinical medicine, investment banking, biopharmaceutical companies, research and academic institutions, and strategy consulting. For many years now, he has focused on the strategic and commercial analysis of cell and gene therapies and regenerative medicines. He is also Head of Cell and Gene Therapy at Juvenescence.
Andrea E. Park, CPA (inactive)
CHIEF FINANCIAL OFFICER
Andrea E. Park, CPA (inactive) was appointed as Chief Financial Officer of AgeX Therapeutics, Inc. in May 2020. Prior to that, Ms. Park served as the company’s VP of Finance and Controller since October 2019. As CFO, Ms. Park is responsible for all of the company’s financial functions including accounting, internal and external audits, tax, and treasury. Ms. Park’s career spans over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as VP of Finance and Controller from June 2016 to September 2019 and as Corporate Controller from February 2005 to June 2016 for Lineage Cell Therapeutics, Inc. (NYSE American: LCTX). While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., Oncocyte Corporate and AgeX. Earlier in her career she has worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.
Hal Sternberg, Ph.D.
VP, RESEARCH
Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.
Judith Segall
DIRECTOR – ADMINISTRATION
CORPORATE SECRETARY
Judith Segall is our Director of Administration and Corporate Secretary. Prior to joining AgeX, Ms. Segall was the Vice President of Administration of BioTime, Inc. As one of BioTime’s co-founders in 1990, she served on the BioTime Board of Directors and as an executive for over 25 years. Ms. Segall received her B.S. in Nutrition and Clinical Dietetics from the University of California at Berkeley.
Board of Directors
Joanne M. Hackett, Ph.D.
Chairperson
Dr. Joanne M. Hackett is the Head of Genomic and Precision Medicine at IQVIA. IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. From 2017 to 2020 Dr. Hackett served as Chief Commercial Officer of Genomics England, where she engaged industry, academia and the clinical community to achieve the goal of sequencing genomes of patients and families of patients with rare diseases, and patients with common cancers. Genomics England is owned by the Department of Health and Social Care in the United Kingdom.
During 2016 and 2017 Dr. Hackett served as Chief Commercial Officer and Interim Chief Executive Officer of Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing, delivering and commercializing precision medicine. Dr. Hackett served as Director of Commercial Development for UCLPartners in London, England from 2013 – 2016. UCLPartners is focused on co-creating, testing and implementing innovative healthcare solutions with its academic and healthcare partners, and fostering the wider spread and adoption of those solutions. Previously, she served as Chief Operating Officer and Research Lead at Cambridge University Health Partners, and she has held other positions in the biomedical industry and in academia, including as a research scientist, and she has served on a number of advisory committees and advisory boards in the biomedical and healthcare fields.
Dr. Hackett holds a PhD in Molecular Genetics from the University of New Brunswick.
Michael D. West, Ph.D.
Founder and CEO
Dr. West is Chief Executive Officer of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cell senescence. He has focused his academic and business career on the application of developmental biology to age-related degenerative disease.
He was the founder and first CEO of Geron Corporation (Nasdaq: GERN) and from 1992 to 1998, he was variously, CEO, Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998, while at Geron he organized and managed the research collaboration between the company and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells.
From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. At ACT, he managed programs in reprogramming developmental aging using somatic cell nuclear transfer, retinal differentiation, and PureStem, a technology for the multiplex derivation and characterization of diverse clonal human embryonic progenitor cell lines.
From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX), where he led BioTime’s efforts to acquire Geron’s stem cell assets, now residing in the BioTime subsidiary Asterias Biotherapeutics (NYSE American: AST); the development of OpRegen for age-related macular degeneration; Renevia, a matrix for lipotransfer; and diverse novel preclinical programs in orthopedics and other applications in regenerative medicine.
At AgeX Therapeutics, he currently leads preclinical-stage programs in metabolic and vascular aging as well as induced Tissue Regeneration (iTR).
Gregory Bailey, M.D.
Gregory Bailey, M.D., is CEO of Juvenescence Limited, a company that develops therapeutics, so people can have healthier, longer lives.
Dr. Bailey has been founding and financing life science companies since 1995. Some of these companies have traded on NASDAQ, AIM, AMEX and NYSE, reaching over $18 billion in market capitalization. He co-founded Ascent Health Care in 1995, which was sold to Stryker for $525 million in 2009. In 2004, he was the initial financier and a board member of Medivation, Inc. (MDVN: NASDAQ). It was ultimately acquired by Pfizer in September 2016 for $14.3 billion. In January 2014, Dr. Bailey along with his partners capitalized Biohaven through Portage Biotech with $3.5 million, subsequently adding a further $3.5 million over the next two years. Biohaven went public May 2017 on NYSE. Portage was the major shareholder in Biohaven until it did a dividend of $210 million of Biohaven shares to Portage shareholders. Dr. Bailey remains a major shareholder of Biohaven, which has a market cap of a little over $1.5 billion.
Along with AgeX, Gregory Bailey currently sits on the Board of Directors of three public companies: Portage Biotech, Inc. (PTGEF:OTC); SalvaRx PLC. (SALV.L:AIM); and Biohaven Pharmaceutical Holding Company Ltd. (BHVN:NYSE).
Dr. Bailey received his medical doctorate from the University of Western Ontario.
Michael H. May, Ph.D
Dr. Michael May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.
He is President and Chief Executive Officer of CCRM. Prior to CCRM, Dr. May was the President and co-founder of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.
Dr. May sits on a number of boards and advisory committees including the Centre for the Commercialization of Antibodies and Biologics (CCAB); the Entrepreneurship Leadership Council at the University of Toronto; the TO Health! Human & Science Steering Committee; the Cell and Gene Therapy Insights, Editorial Advisory Board; Member Commercialization Committee of the International Society for Cell Therapy (ISCT); and the Executive Committee, Alliance for Regenerative Medicine (ARM). He is the Chairman of the start-up company ExCellThera Ltd.